Circulating Tumor DNA Using Tagged Targeted Deep Sequencing to Assess Minimal Residual Disease in Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy.
In breast cancer patients undergoing neoadjuvant chemotherapy before surgery, there is an unmet need for non-invasive biomarkers predictive of response. Analysis of DNA circulating tumor (ctDNA) in particular has been the object of several reports, but some of them have studied the application of targeted sequencing marked in (tTDS) for clinical practice and performance compared to digital droplet PCR (ddPCR). Here, we present the first results of an ongoing study involving prospectively accrued, monocentric cohort patients with invasive breast cancer, underwent neoadjuvant chemotherapy followed by surgery with curative intent as per clinical practice.
A pretreatment tumor biopsies and plasma samples were collected before and during treatment, after surgery, and every six months thereafter or until relapse, whichever comes first. pretreatment biopsies were sequenced with 409-gene panel large parallel sequencing (MPS), which enable the identification of mutations in the target and their research in plasma by tTDS and ddPCR as complementary approaches. Using tTDS, we showed the presence of at least one deleterious mutations in all cases of relapse we study (n = 4), with an average lead time of six months before clinical relapse. Association with ddPCR is suboptimal, and only one patient relapse can be identified by the method. tTDS shows potential as a non-invasive method for the early detection of MRD in patients with SM.
Next-generation sequencing (NGS) an interesting alternative approach to PCR-based characterization of plant genetic engineering for security assessment and labeling since NGS is highly sensitive in detecting insertion of T-DNA and vector backbone sequences in transgenic plants. In this study, two transgenic lines independent male Populus tremula, T193-2 and T195-1, both of which carry the gene FLOWERING LOCUS T of Arabidopsis thaliana under the control of the heat-inducible promoter (pHSP :: AtFT) and non-transgenic control W52 clone, which is further characterized by NGS and third generation sequencing.
Circulating Tumor DNA Using Tagged Targeted Deep Sequencing to Assess Minimal Residual Disease in Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy.
The results support previous findings that T-DNA hemizygously included in the genomic loci of each line. However, T-DNA insertion consists of a conglomeration of one or two copies of the T-DNA together with T-DNA fragments smaller without AtFT section. Based on data from NGS, no extra pieces of T-DNA or vector backbone sequences can be identified in the genome of two transgenic lines. Therefore, the seeds derived from a cross between pHSP :: AtFT elderly male and female transgenic wild plants are expected T-DNA vector backbone fragment or free. Thus, PCR analysis of strengthening the T-DNA fragment with a primer AtFT partial specific enough to determine whether or not the transgenic seeds.
Description: WDR61 (WD-repeat-containing protein 61), also known as SKI8 or REC14, is a subunit of the human PAF and SKI complexes, which function in transcriptional regulation and are involved in events downstream of RNA synthesis, such as RNA surveillance (1,2). PAF1C is implicated in regulation of development and maintenance of embryonic stem cell pluripotency. Component of the SKI complex which is thought to be involved in exosome-mediated RNA decay and associates with transcriptionally active genes in a manner dependent on PAF1C (3,4).
Description: WDR61 (WD-repeat-containing protein 61), also known as SKI8 or REC14, is a subunit of the human PAF and SKI complexes, which function in transcriptional regulation and are involved in events downstream of RNA synthesis, such as RNA surveillance (1,2). PAF1C is implicated in regulation of development and maintenance of embryonic stem cell pluripotency. Component of the SKI complex which is thought to be involved in exosome-mediated RNA decay and associates with transcriptionally active genes in a manner dependent on PAF1C (3,4).
Description: A polyclonal antibody against WDR61. Recognizes WDR61 from Human, Mouse. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IHC; Recommended dilution: WB:1:500-1:2000, IHC:1:20-1:200
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human WDR61 . This antibody is tested and proven to work in the following applications:
Description: A polyclonal antibody against WDR61. Recognizes WDR61 from Human. This antibody is HRP conjugated. Tested in the following application: ELISA
Description: A polyclonal antibody against WDR61. Recognizes WDR61 from Human. This antibody is FITC conjugated. Tested in the following application: ELISA
Description: A polyclonal antibody against WDR61. Recognizes WDR61 from Human. This antibody is Biotin conjugated. Tested in the following application: ELISA
Description: Human WDR61 knockdown cell line is engineered by our optimized transduction of the specific shRNA with lentivirus. Knockdown levels are determined via qRT-PCR. Gentaur offers generation of stable knockdown (RNAi) cell lines expressing shRNAs targeting genes of your interest.
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human WDR61 (N-Terminus). This antibody is tested and proven to work in the following applications:
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human WDR61 - N-terminal region. This antibody is tested and proven to work in the following applications:
